Merck & Co. Inc. hopes to boost sales of its combination antibiotic Zerbaxa by adding hospital-acquired bacterial pneumonia to its labeling, but even with Phase III data in hand showing non-inferiority to meropenem in that setting, the value proposition for this indication is uncertain.
On Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?